RRE Ventures (NASDAQ: RREVU) CEO awarded 250,000 warrants and 525,000 Class B shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
RRE Ventures Acquisition Corp. director and CEO Philip Kassin reported awards of warrants and convertible sponsor shares rather than open‑market trades. He received 250,000 private placement warrants at $1.00 per warrant, each exercisable for one Class A Ordinary Share at $11.50 per share. Earlier awards added 450,000 and 75,000 Class B Ordinary Shares, which are convertible into Class A on a one‑for‑one basis in connection with the company’s initial business combination. After these grants, he directly holds 250,000 warrants and 525,000 Class B shares, with no sales or dispositions reported.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Kassin Philip (Phil)
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Warrant | 250,000 | $1.00 | $250K |
| Grant/Award | Class B Ordinary Shares | 75,000 | $0.00 | -- |
| Grant/Award | Class B Ordinary Shares | 450,000 | $0.00 | -- |
Holdings After Transaction:
Warrant — 250,000 shares (Direct, null);
Class B Ordinary Shares — 525,000 shares (Direct, null)
Footnotes (1)
- The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares at the time of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date. These securities were previously reported on a Form 3 filed by the Reporting Person. The private placement warrants will become exercisable 30 days after the completion of the Issuer's initial business combination and will expire five years after the completion of the Issuer's initial business combination or earlier upon liquidation.
Key Figures
Private placement warrants granted: 250,000 warrants
Warrant exercise price: $11.50 per share
Initial Class B grant: 450,000 shares
+4 more
7 metrics
Private placement warrants granted
250,000 warrants
Grant on 2026-05-01 at $1.00 per warrant
Warrant exercise price
$11.50 per share
Each warrant exercisable into one Class A Ordinary Share
Initial Class B grant
450,000 shares
Class B Ordinary Shares granted on 2026-03-02
Additional Class B grant
75,000 shares
Class B Ordinary Shares granted on 2026-03-18
Class B shares after latest grant
525,000 shares
Total Class B Ordinary Shares following 2026-03-18 transaction
Underlying Class A shares
250,000 shares
Shares underlying private placement warrants
Underlying Class A from Class B
525,000 shares
Potential Class A upon one-for-one conversion of Class B
Key Terms
Class B Ordinary Shares, initial business combination, private placement warrants, Form 3, +1 more
5 terms
initial business combination financial
"at the time of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person"
An initial business combination is the deal in which a special-purpose acquisition company (SPAC) merges with or acquires an operating business to bring that business onto public markets. Think of the SPAC as an empty shell that raises money from investors, then uses that cash to buy a private company—this transaction turns the private company into a public one and often changes its ownership, valuation, and access to capital, so investors should watch for shifts in risk, future growth prospects, and shareholder rights.
private placement warrants financial
"The private placement warrants will become exercisable 30 days after the completion of the Issuer's initial business combination"
Private placement warrants are tradable coupons given directly to a limited group of investors that let the holder buy a company's shares at a fixed price before a set expiration date. They matter to investors because they can provide extra upside if the stock rises and give companies a way to raise money outside a public offering, but they also can increase the number of shares outstanding (dilution) and therefore affect share value and investor returns.
Form 3 regulatory
"These securities were previously reported on a Form 3 filed by the Reporting Person"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
FAQ
What insider transactions did RRE Ventures (RREVU) CEO Philip Kassin report?
Philip Kassin reported three equity awards, not open‑market trades. He received 250,000 private placement warrants at $1.00 each and two grants of Class B Ordinary Shares totaling 525,000 shares, all convertible into Class A Ordinary Shares in connection with the company’s initial business combination.
How many warrants did the RRE Ventures (RREVU) CEO receive and on what terms?
The CEO received 250,000 private placement warrants at $1.00 per warrant. Each warrant is exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share, becoming exercisable 30 days after completion of the initial business combination and expiring five years thereafter or upon liquidation.
Did the RRE Ventures (RREVU) Form 4 show any stock sales or dispositions?
No sales or dispositions are reported in this Form 4. All three transactions use code A for grants or other acquisitions. The filing shows only awards of warrants and Class B Ordinary Shares, with no open‑market purchases, sales, tax‑withholding dispositions, or gifts disclosed.
When can RRE Ventures (RREVU) private placement warrants be exercised?
The private placement warrants become exercisable after the SPAC’s business combination. They are exercisable starting 30 days after completion of the issuer’s initial business combination and expire five years after that date, or earlier if the issuer is liquidated, as described in the footnotes.